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re-analysed if not analysed by intention-to-treat. The summary
effect estimate (Relative Risk, RR) was calculated by meta-analy-
sis using a ﬁxed effects model by the Mantel-Haenszel method.
The quality of RCTs included in the meta-analysis was judged
according to the method of randomisation and concealment of
allocation of treatments (as this is the element of RCT design
likely to introduce the most bias). Publication bias was assessed
using funnel plots. RESULTS: Of the 133 papers initially iden-
tiﬁed in the literature search, only 8 were found to be head-to-
head comparisons of a standard dose of PPI compared with
esomeprazole 40 mg. This total was reduced to six when the
quality of the RCTs was assessed. From the 6 trials, a meta-
analysis of endoscopic healing rates of esomeprazole 40 mg com-
pared with standard-dose PPIs gave the following RESULTS: At
4 weeks, RR 0.92 (95% CI: 0.90 to 0.94, p < 0.00001); at 8
weeks, RR 0.95 (95% CI: 0.94 to 0.97, p < 0.00001). The effect
of using all eight trials in the meta-analysis made small numeri-
cal differences to the overall estimates but did not change the
direction or make a signiﬁcant difference non-signiﬁcant. Publi-
cation bias did not appear to have a signiﬁcant impact on the
results, as there was no apparent asymmetry identiﬁed in the
assessment of funnel plots. CONCLUSIONS: Esomeprazole
demonstrates signiﬁcantly higher endoscopic healing rates when
compared to standard-dose PPIs.
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OBJECTIVE: To show the efﬁcacy of orally administered
esomeprazole 40 mg (ESO) in patients with erosive gastro-
oesophageal reﬂux disease (GERD) in Mexico. METHODS: We
conducted an open label, prospective cohort study in 22 centers
in Mexico, between June 2001 and July 2002, with patients
being 18–86 years old, diagnosed with endoscopy-conﬁrmed
erosive (GERD) and classiﬁed according to Los Angeles Classi-
ﬁcation (LAC). Patients were treated with ESO 40 mg for a 4–8
week period. According to LAC, effectiveness was measured by
the reﬂux-oesophagitis healing at 4 and 8 weeks, deﬁned as the
absence of macroscopic mucosal lesions. Symptoms and general
evaluation of the treatment were secondary end points. Presence
of Helicobacter pylori was assessed by clotest. The study was
analyzed using the ITT population. Healing at the 4 and 8 week
endpoints was assessed with the McNemar test (p < 0.05, 95%
CI). RESULTS: A total of 213 patients were included in the
study: 53.52% were males, and the average age was 44.2 years
(±14.63). 78.88% were diagnosed with mild to moderated
GERD (Grades A & B LAC), and 38.97% were positive for 
Helicobacter pylori. Using gastro-oesophageal endoscopy as 
the assessment method, GERD healing rate after the 4 and 
8 weeks period with esomeprazole 40 mg were 88.73%
(84.48%–92.98%, 95% CI) and 94.84% (91.87%–97.81%,
95% CI) respectively. No serious adverse events were reported.
Treatment with esomeprazole 40 mg was well tolerated. CON-
CLUSIONS: Esomeprazole 40 mg proved to be effective and
secure for the GERD treatment in the Mexican patients.
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OBJECTIVES: To compare the clinical and cost-effectiveness of
esomeprazole and other PPI (omeprazole, lansoprazole, panto-
prazole and rabeprazole) in patients with GERD. METHODS:
The clinical effectiveness analysis according Cochrane Collabo-
ration guidelines was performed. Cost-effectiveness decision
model was performed from a payer’s perspective, with a time
horizon of 8 weeks. RESULTS: 8, 13, 6, and 3 RCT comparing
esomeprazole to lansoprazole, omeprazole, pantoprazole and
raboprazole were included. Esomeprazole 40 mg was signiﬁ-
cantly more effective compared to lansoprazole 30 mg and
omeprazole 20 mg in healing reﬂux esophagitis after 4 and 8
weeks (OR = 1.25 and 1.29 vs. lansoprazole; OR = 1.84 and
2.10 vs. omeprazole). Esomeprazole is also more effective than
lansoprazole and omeprazole for variables evaluating reﬂux
symptoms. Compared to pantoprazole 40 mg, esomeprazole 40
mg was statistically signiﬁcantly more effective in terms of
healing erosive oesophagitis after 4–6 and 8–10 weeks (OR =
1.35 and 1.36, respectively), time to reach sustained heartburn
resolution and proportion of heartburn-free days. Result of a
single trial showed that pantoprazole resulted in faster ﬁrst-time
relief from GERD-related symptoms than esomeprazole. Based
on a single study comparing esomeprazole 20 mg and rabepra-
zole 10 mg in patients with non-erosive GERD, both treatments
had similar efﬁcacy in relief of symptoms. Triple therapy regi-
mens with either esomeprazole or omeprazole were similarly
effective in eradicating Helicobacter pylori. The safety analysis
showed no signiﬁcant differences in the frequency of adverse
events between esompeprazole and other PPI except for
headaches, which occurred more frequently in the desloratadine
group than in the lansoprazole group. The ICER for esomepra-
zole per additional patient healed after 8 weeks was 7858 PLN
(vs lansoprazole), 2608 PLN (vs lansoprazole) and 6274 PLN
(vs. pantoprazole). CONCLUSIONS: Esomeprazole is at least as
effective as other PPI in the treatment of GERD.
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OBJECTIVES: Mycophenolate mofetil (MMF) has been associ-
ated with increased risk of gastrointestinal (GI) complications in
transplant recipients. Our aim was to assess the risk of GI med-
ication use in heart transplant patients receiving MMF and their
health care costs over a two-year period. METHODS: US com-
mercial claims data for 233 patients receiving heart transplants
between 1995 and 2005 were linked to data from the Organ Pro-
curement Transplant Network. Patients were placed into two
groups: received MMF (MMF group) and did not (non-MMF
group). MMF recipients were identiﬁed as having ≥1 pharmacy
claim post-transplant for MMF. For the MMF group, use of GI
medications was deﬁned as having ≥1 prescription (H2 antago-
nists, proton pump inhibitors, and miscellaneous GI agents)
during the year following the initial claim for MMF. For those
in the non-MMF group, the commensurate 1-year period post-
transplant in which the GI claim occurred was deﬁned based on
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the median time to the ﬁrst MMF claim of the MMF group. A
multivariate logistic regression and a Wilcoxon test were
employed to assess risk of GI medication use and total medical
costs 1 year before and after occurrence of GI medication claim,
respectively. RESULTS: MMF was received by 173 (74%)
patients. GI medication use occurred in 139 (80%) of the
patients in the MMF group and in 29 (48%) of the patients in
the non-MMF group. Patients who received MMF were associ-
ated with a statistically signiﬁcant increase in risk of GI med-
ication use compared to patients who did not receive MMF (OR
= 7.65, p < 0.0001). Patients using GI medications generated sig-
niﬁcantly greater costs compared to patients not using GI med-
ications ($69,328 vs $48,301, p < 0.0001). CONCLUSIONS:
Heart transplant recipients who receive MMF had 7.7 times
greater risk of using GI medications compared to those who did
not receive MMF, which leads to increased costs.
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OBJECTIVE: To assess the economic consequences of changing
the prescription pattern of proton pump inhibitors (PPI) in
Sweden by use of a budget impact model (BIM). METHODS:
Data from published sources provided information about treat-
ment effects of different PPIs and productivity losses due to
upper gastrointestinal symptoms (GIS). Sale statistics at the
county council level and ofﬁcial Swedish price lists were used to
estimate drug costs. Data on wages ware taken from Statistics
Sweden and was used to estimate indirect costs. The BIM was
ﬂexible and allowed us to analyse (i) the drug budget impact in
a particular county council of switching between different PPIs
and (ii) the annual per patient drug cost and the indirect cost
from treating patients with different PPIs during a speciﬁc time
period. RESULTS: In the county council of Stockholm (1.9
million inhabitants) the annual PPI drug costs amount to about
€11.5 Million of which 50% and 14% comprise of generic
omeprazole and esomeprazole, respectively. The consequence of
switching from generic omeprazole to esomeprazole for 30% of
the patients would result in increasing the PPI drug costs by
11%. However, as the major part of the annual per patient costs
comprise of indirect costs due to productivity losses and absence
from work, esomeprazole only need to be 1–2 percent units more
effective in reducing GIS per week than generic omeprazole to
compensate for its higher price. CONCLUSION: The results
indicate the importance of including both direct and indirect
costs in BIMs when analyzing changes in drug prescription 
patterns.
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OBJECTIVES: Infection with Helicobacter pylori (HP) is asso-
ciated with several clinical conditions; the two most important
in both numbers and costs are peptic ulcer disease and gastric
cancer. In 1999 these two conditions were responsible for more
than 2000 deaths and €94.9 million of direct medical costs in
The Netherlands. A great step forward would be the develop-
ment of a preventive vaccine. The objective of this study is to
estimate the cost-effectiveness of a potential HP vaccine for The
Netherlands. METHODS: We designed a probabilistic Markov
model to fully incorporate the uncertainty associated with the
different transition probabilities. The model followed a birth
cohort during a period of 85 years. Transition probabilities for
the current situation without vaccination were based on Dutch
data. In presence of vaccination these probabilities were adjusted
using the attributive risks and vaccine efﬁcacy. Vaccine efﬁcacy
was assumed at 80% (range: 50–100). The perspective of the
analysis was that of the health care sector; only Dutch direct
medical costs were taken into account. For cost per dose we per-
formed different scenario analyses (base case: €50). For each 
scenario we conducted 10.000 Monte Carlo simulations. Cost-
effectiveness is expressed as net costs per life year gained (LYG)
where costs and effects were discounted according to the current
Dutch guidelines for pharmacoeconomic research (costs: 4%,
effects: 1.5%). RESULTS: For the base case scenario the median
cost-effectiveness ratio is estimated €2700 per LYG. For all sce-
narios investigated cost-effectiveness is estimated below the
informal Dutch threshold of €20,000 per LYG with a probabil-
ity of more than 0.95. CONCLUSIONS: According to our
model, for the greater part based on Dutch data, a potential new
developed HP vaccine could be considered cost-effective as the
cost-effectiveness is estimated below the informal Dutch thresh-
old used by decision makers.
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OBJECTIVES: A pentavalent rotavirus vaccine to prevent
rotavirus gastroenteritis (RVGE) in children will soon become
available. The objective of the study reported here was to assess
the health outcomes and the economic impact in the UK of a RV
vaccination programme vs no programme. METHODS: A birth
cohort was followed up to age 5 using a cohort model. Epi-
demiological parameters were taken from the REVEAL study (a
prospective epidemiological study conducted in the UK, 2004–
2005) and from literature. Costs were assessed from NHS and
societal perspectives by combining health care resource utiliza-
tion collected in REVEAL study and unit costs from ofﬁcial
sources. ITT effectiveness of the vaccine was taken from a large
worldwide clinical trial (70,000 children). Health outcomes
included home care cases, telephone consultations, GP/Acci-
dent&Emergency department visits, hospitalisations and noso-
comial infections. A sensitivity analysis was performed varying
the cost of the RV vaccine course between £80 and £100.
RESULTS: The model estimates that the introduction of a RV
vaccination programme with the pentavalent RV vaccine (90%
coverage rate) would reduce the RVGE burden by 75% in the
UK: 102,290 home care cases, 25,570 telephone consultations,
83,220 GP visits, 5660 Accident&Emergency department visits,
12,220 hospitalisations and 5040 nosocomial infections could be
avoided. The RVGE cost was estimated at £29m and £69m from
NHS and societal perspectives respectively. The introduction of
a RV vaccination programme would reduce the RVGE cost by
about 75% in both perspectives. For a vaccine course ranging
from £80 to £100, the RV vaccination programme is associated
with an incremental cost-effectiveness ratio that varies from
